International Online Medical Council (IOMC)

Short Communication

Pages: 1 - 4

Benefit-Risk of Immunomodulators in Multiple Sclerosis. Alemtuzumab and Next?

Review Article

Pages: 1 - 7

Diversity of Neuromyelitis Optica: Inner City Hospital Experience and Review of Literature

Harini Sarva, Ariel Antezana, Johanne Policard, Diana Rojas-Soto, Yassir El-Sherif, Ilya Kister, Steven Pulitzer and Yaacov Anziska

DOI: 10.4172/2155-9562.1000189

Research Article

Pages: 1 - 9

Extent of Cerebrovascular Disruption Following Blast Exposure is Influenced by the Duration of the Positive Phase in Addition to Peak Overpressure

Dexter V Reneer, Carolyn A Crowdus, Sarbani Ghoshal, Julie Corkins, Richard D Hisel, Braden T Lusk and James W Geddes

DOI: 10.4172/2155-9562.1000188

Review Article

Pages: 1 - 6

EEG and SPECT Changes in Acute Ischemic Stroke

Suman Bhattarai, ZHANG Xiao-ning and Tuerhong Tuerxun

DOI: 10.4172/2155-9562.1000190

Case Report

Pages: 1 - 3

Increasing Stimulation Parameters Relieves Acquired Eyelid Apraxia after Deep Brain Stimulation of the Subthalamic Nucleus

Akin Akakin, Baran Yilmaz, Nazire Afsar and Turker Kilic

DOI: 10.4172/2155-9562.1000191

Review Article

Pages: 1 - 7

Remyelination in Multiple Sclerosis – How Close are We?

Filipe Palavra, Flávio Reis and Luís Almeida

DOI: 10.4172/2155-9562.1000192

Research Article

Pages: 1 - 6

Prospective, Longitudinal, Multicenter Observational Study of Long-term Treatment with Intramuscular Interferon Î²-1a of Patients with Clinically Isolated Syndrome at High Risk of Conversion

Hernández Miguel Ángel, Prieto, José María, Arnal Carmen, Sánchez Fernando and Izquierdo Guillermo

DOI: 10.4172/2155-9562.1000193

Research Article

Pages: 1 - 6

Self-efficacy, Physical Activity and QOL in People with MS

Cecilie Fjeldstad and Gabriel Pardo

DOI: 10.4172/2155-9562.1000194

Research Article

Pages: 1 - 4

Hyponatremia and Voltage Gated Potassium Channel Antibody Associated Limbic Encephalitis

Newey CR and Sarwal A

DOI: 10.4172/2155-9562.1000195

Commentary

Pages: 1 - 2

Alemtuzumab: The Right Choice in the Management of Relapsingremitting Multiple Sclerosis?

Murat Yildiz and Barbara Tettenborn

DOI: 10.4172/2155-9562.1000196

Journal of Neurology & Neurophysiology

Volume 5, Issue 2, 2014

Benefit-Risk of Immunomodulators in Multiple Sclerosis. Alemtuzumab and Next?

Diversity of Neuromyelitis Optica: Inner City Hospital Experience and Review of Literature

Extent of Cerebrovascular Disruption Following Blast Exposure is Influenced by the Duration of the Positive Phase in Addition to Peak Overpressure

EEG and SPECT Changes in Acute Ischemic Stroke

Increasing Stimulation Parameters Relieves Acquired Eyelid Apraxia after Deep Brain Stimulation of the Subthalamic Nucleus

Remyelination in Multiple Sclerosis – How Close are We?

Prospective, Longitudinal, Multicenter Observational Study of Long-term Treatment with Intramuscular Interferon Î²-1a of Patients with Clinically Isolated Syndrome at High Risk of Conversion

Self-efficacy, Physical Activity and QOL in People with MS

Hyponatremia and Voltage Gated Potassium Channel Antibody Associated Limbic Encephalitis

Alemtuzumab: The Right Choice in the Management of Relapsingremitting Multiple Sclerosis?

Journal Highlights

Journal Flyer

+1-845-458-6882